Getagraph.com logo
S&P 500
(1.26%) 5 127.79 points
Dow Jones
(1.18%) 38 676 points
Nasdaq
(1.99%) 16 156 points
Oil
(-1.22%) $77.99
Gas
(5.65%) $2.15
Gold
(0.02%) $2 310.10
Silver
(-0.16%) $26.79
Platinum
(0.38%) $966.30
USD/EUR
(-0.36%) $0.929
USD/NOK
(-1.07%) $10.87
USD/GBP
(-0.11%) $0.797
USD/RUB
(0.36%) $91.45

Sanntidsoppdatering for Syndax Pharmaceuticals [SNDX]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
Upcoming Earnings Alert

2 days till quarter result
(amc 2024-05-06)

Expected move: +/- 6.45%

BUY
80.00%
return 4.54%
SELL
40.00%
return 0.25%
Sist oppdatert3 mai 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

0.87% $ 22.05

KJøP 113962 min ago

@ $22.05

Utstedt: 14 feb 2024 @ 21:38

Avkastning: 0.00%

Forrige signal: feb 13 - 21:50

Forrige signal: Selg

Avkastning: 4.26 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD)...

Stats
Dagens volum 583 893
Gjennomsnittsvolum 1.10M
Markedsverdi 1.87B
EPS $0 ( 2024-02-27 )
Neste inntjeningsdato ( $0 ) 2024-05-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -7.40
ATR14 $0.0150 (0.07%)
Insider Trading
Date Person Action Amount type
2024-02-07 Metzger Michael A Buy 214 500 Stock Options (Right to buy)
2024-02-07 Metzger Michael A Buy 39 000 Common Stock
2024-02-07 Metzger Michael A Buy 107 250 Common Stock
2024-02-07 Goldan Keith A. Buy 70 000 Stock Options (Right to buy)
2024-02-07 Goldan Keith A. Buy 11 700 Common Stock
INSIDER POWER
46.07
Last 97 transactions
Buy: 2 711 593 | Sell: 1 085 664

Volum Korrelasjon

Lang: -0.03 (neutral)
Kort: 0.43 (neutral)
Signal:(67.581) Neutral

Syndax Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
IDLB0.85
NWS0.846
NWSA0.832
ARVN0.824
BAFN0.824
CENTA0.821
ISDX0.821
CVCY0.817
ADRE0.817
CIGI0.812
10 Mest negative korrelasjoner
VERX-0.833
RMRM-0.832

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Syndax Pharmaceuticals Korrelasjon - Valuta/Råvare

The country flag 0.88
( strong )
The country flag 0.69
( moderate )
The country flag 0.00
( neutral )
The country flag 0.75
( moderate )
The country flag -0.17
( neutral )
The country flag 0.13
( neutral )

Syndax Pharmaceuticals Økonomi

Annual 2023
Omsetning: $0
Bruttogevinst: $-12 000.00 (0.00 %)
EPS: $-2.98
FY 2023
Omsetning: $0
Bruttogevinst: $-12 000.00 (0.00 %)
EPS: $-2.98
FY 2022
Omsetning: $0
Bruttogevinst: $-454 000 (0.00 %)
EPS: $-2.37
FY 2021
Omsetning: $139.71M
Bruttogevinst: $0.00 (0.00 %)
EPS: $0.480

Financial Reports:

No articles found.

Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.